Here are the most clinically significant terms and keywords extracted from the guideline, organized by relevance:

### **Core Concepts & Conditions**  
- **Venous Thromboembolism (VTE)**  
- **Deep Vein Thrombosis (DVT)**  
- **Pulmonary Embolism (PE)**  
- **Thromboprophylaxis**  
- **Thrombophilia** (e.g., **factor V Leiden**, **protein S deficiency**, **antiphospholipid syndrome**)  
- **Hyperemesis Gravidarum (HG)**  
- **Ovarian Hyperstimulation Syndrome (OHSS)**  
- **COVID-19** (pro-thrombotic risk)  

### **Clinical Management & Interventions**  
- **Low Molecular Weight Heparin (LMWH)** (primary prophylaxis/treatment)  
- **Fondaparinux** (alternative, requires hematologist consultation)  
- **Warfarin** (restricted use in pregnancy)  
- **DOACs** (avoided in pregnancy/breastfeeding)  
- **Aspirin** (not for thromboprophylaxis; only if other indications)  
- **Anti-embolic (TED) stockings**  
- **Wound drains** (for cesarean section on LMWH)  

### **Risk Assessment & Referral**  
- **Pre-pregnancy counseling**  
- **Antenatal/postnatal risk assessment**  
- **Joint Obstetric Haematology Clinic (JOHC)** (key referral point)  
- **Maternal Medicine Clinic**  
- **Immediate referral** (for thrombophilia, recurrent VTE)  

### **Timing & Contraindications**  
- **Early initiation** (thromboprophylaxis in pregnancy)  
- **Postpartum LMWH** (start 6 hours after birth)  
- **Contraindications**:  
  - Active bleeding  
  - Labor onset  
  - LMWH allergy  
  - Specific bleeding risks  

### **Diagnosis & Monitoring**  
- **Compression duplex ultrasound** (DVT)  
- **V/Q scan** or **CTPA** (PE)  
- **Prompt imaging** (suspected VTE)  

### **Dosing & Administration**  
- **LMWH dosing**:  
  - Prophylactic vs. treatment (1mg/kg BD for VTE)  
  - Syringe strengths (40mg, 60